Cardiac-valvular EDS

Cardiac-valvular Ehlers-Danlos syndrome is the EDS subtype where the heart valves fail. The skin and joint findings are present, but they are the supporting evidence rather than the clinical anchor. The clinical anchor is severe progressive mitral and aortic regurgitation. The condition leads to valve repair or replacement in adulthood for most affected individuals, and the cause of death without surgical intervention is heart failure or arrhythmia from valvular disease.

The molecular biology

Cardiac-valvular EDS is autosomal recessive. The gene is COL1A2, encoding the alpha-2 chain of type I collagen. Two functional alleles of COL1A2 are required to produce the alpha-2 chain in the heterotrimeric type I procollagen molecule, which has the composition two alpha-1 plus one alpha-2. When biallelic loss-of-function variants in COL1A2 abolish alpha-2 chain production, type I collagen molecules form as alpha-1 homotrimers. The homotrimeric form is a structurally inferior collagen.

The clinical picture is the consequence of weakened type I collagen in a tissue that depends on it heavily. The valve leaflets, the chordae tendineae, the aortic root, and the skin all suffer. The joints suffer less because joint hypermobility in cvEDS is generally milder than in classical or hypermobile EDS.

Clinical features

The valvular disease is the central problem. Mitral valve prolapse with progressive mitral regurgitation typically develops in adolescence or early adulthood. Aortic regurgitation, often with aortic root dilation, develops on a similar timeline. Without intervention, the volume overload from severe regurgitation produces left ventricular dilation, heart failure, and arrhythmia. Surgical valve repair or replacement, often combined with aortic root replacement, is the standard intervention. The age at first surgery varies but typically falls between the second and fourth decades.

Skin findings include hyperextensibility, atrophic scarring, and easy bruising, similar to classical EDS but generally milder. Joint hypermobility is present and tends to involve small joints more than large ones. Hernia, pelvic floor prolapse, and other classical EDS features can occur.

The cvEDS phenotype was described after the recognition that some families with severe progressive valvular disease and connective tissue findings carried biallelic COL1A2 mutations distinct from those associated with osteogenesis imperfecta or other COL1A2-related conditions.

Diagnosis

Diagnosis is by clinical recognition of severe progressive valvular disease in the context of skin and joint findings, supported by COL1A2 sequencing demonstrating biallelic loss-of-function variants. The 2017 international classification specifies major and minor criteria. cvEDS is rare. Reported cases worldwide number in the dozens to low hundreds. The true prevalence is unknown.

What management looks like

There is no FDA-approved disease-specific drug therapy. Standard of care has two components: cardiac surveillance and surgical management of valvular disease, plus the supportive measures common to other EDS subtypes for skin and joint findings.

Cardiac surveillance includes baseline echocardiography at diagnosis, followed by periodic repeat imaging (typically annual or more often once mitral or aortic regurgitation is detected) to track valve function and aortic root dimensions. The threshold for surgical intervention follows standard valve disease guidelines: severe regurgitation with developing left ventricular dilation, symptoms, or pulmonary hypertension. The presence of cvEDS leaves the threshold for surgery unchanged. What changes is the surgical complexity.

Valve surgery in cvEDS is technically more difficult than in unaffected people because the leaflet tissue is fragile and sutures pull through more readily. Some centers prefer mechanical valve replacement over repair when the leaflets are too fragile to hold a repair. Cardiac surgery in cvEDS is concentrated at centers experienced in connective tissue valve disease.

The skin and joint management is supportive: protective skin care, careful wound closure, physical therapy for joint stability, bracing where needed. Genetic counseling addresses the 25 percent recurrence risk for siblings and the implications of carrier status in parents.

What this looks like for a family

A 22-year-old man is referred to cardiology after a heart murmur is detected at a routine physical. Echocardiography shows moderate-to-severe mitral regurgitation with a flail anterior leaflet and a moderately dilated aortic root. He has had skin findings and joint hypermobility since childhood that no one ever framed as a connective tissue disorder. The cardiologist asks about family history. His older sister had a mitral valve replacement at 28. The geneticist takes over. COL1A2 sequencing returns biallelic loss-of-function variants. The diagnosis is cvEDS.

He is monitored with echocardiography every six months. Two years later, the mitral regurgitation is severe and the left ventricle is beginning to dilate. The cardiac surgeon, who has done two prior cvEDS valve repairs, takes him to the operating room. The repair holds. He returns to a normal life with a planned cardiac surveillance schedule and a family that now knows what to watch for.

That is what cvEDS care looks like, in practice. The diagnosis does not change the threshold for valve surgery. It changes who does the surgery, what they expect at the operating table, and what the family knows to look for in everyone else who shares the variant.